HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care solutions, announced a commercial agreement with Beverly Hills-based concierge medical practice Atelier Health, expanding its launch footprint into Southern California. This move completes the company's initial targeted markets alongside New York metro, Dallas and South Florida as it advances commercialization of its cable-free 3D ECG technology for remote cardiac monitoring and preventive cardiology.
The agreement underscores HeartBeam's strategy to partner with concierge cardiology practices that prioritize personalized and accessible cardiac care. Atelier Health, a high-end medical practice in Beverly Hills, will now offer HeartBeam's innovative technology to its patients, enabling cable-free 3D ECG monitoring outside traditional clinical settings.
HeartBeam's platform technology is designed for portable devices that collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG. This allows physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. The technology received FDA clearance for arrhythmia assessment in December 2024 and for the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology enablement.
The expansion into Southern California is significant for the region's patients and healthcare providers. Concierge medicine, which offers enhanced access and personalized care, is increasingly adopting advanced remote monitoring solutions. HeartBeam's technology could reduce the need for in-clinic ECGs, allowing timely detection of cardiac issues and potentially preventing emergencies. For the industry, this partnership signals a growing trend of integrating remote monitoring into premium healthcare services, which could drive broader adoption of such technologies.
The commercial agreement with Atelier Health is part of HeartBeam's broader commercialization strategy. The company has now established a presence in key markets across the United States, positioning itself to capture demand from both concierge practices and potentially larger healthcare systems. The technology's ability to provide actionable heart intelligence remotely aligns with the shift toward value-based care and patient-centric models.
For investors, HeartBeam's progress in expanding its commercial footprint is a positive indicator of market acceptance. The company's focus on high-end concierge practices may provide a valuable beachhead for future expansion into larger healthcare networks. As remote cardiac monitoring becomes more prevalent, HeartBeam's patented 3D ECG technology could become a standard tool for preventive cardiology.
Additional information about HeartBeam and its technology is available in the company's newsroom at https://ibn.fm/BEAT. Details on the cleared indications for use can be found at https://www.heartbeam.com/indications.
